CD79B

What is CD79B protein?

CD79B protein, also known as B-cell antigen receptor complex-associated protein beta chain, is a protein that is involved in B-cell receptor signaling. It is a component of the B-cell receptor (BCR) complex, which plays a crucial role in the activation and function of B cells in the immune system.

CD79B protein is specifically expressed in B cells and is responsible for transducing signals from the BCR to downstream signaling pathways upon antigen recognition. It forms a heterodimer with CD79A protein to form the B-cell antigen receptor complex, which is composed of a membrane-bound immunoglobulin (Ig) molecule and associated CD79A/CD79B heterodimers. This complex is required for the surface expression and signaling of the BCR.

What is the function of CD79B protein?

The main function of CD79B is to transduce signals from the BCR upon antigen recognition. It contains immunoreceptor tyrosine-based activation motifs (ITAMs) in its cytoplasmic tail. Upon binding of antigens to the BCR, CD79B is phosphorylated by the Src family kinases. This phosphorylation leads to the recruitment and activation of downstream signaling molecules, such as Bruton's tyrosine kinase (BTK), which ultimately triggers a cascade of intracellular signaling events necessary for B-cell activation, proliferation, and antibody production.

CD79B related signaling pathway

The CD79B protein is involved in the activation of several signaling pathways, including the BCR signaling pathway, which plays a critical role in B cell development, differentiation, and immune responses. This pathway involves the recruitment and activation of various intracellular signaling molecules, ultimately leading to the activation of transcription factors and gene expression necessary for B cell proliferation, survival, and antibody production.

CD79B Related Diseases

•  B Cell Lymphomas: CD79B is a key component of the B cell receptor (BCR) complex, which plays a crucial role in B cell activation and survival. Mutations or dysregulation of CD79B can contribute to the development of B cell lymphomas, such as diffuse large B cell lymphoma (DLBCL) and Burkitt lymphoma.
•  Agammaglobulinemia: CD79B mutations can also lead to a rare genetic disorder known as X-linked agammaglobulinemia (XLA). XLA is characterized by a severe deficiency in B cells, resulting in a lack of antibody production and increased susceptibility to infections.
•  Autoimmune Diseases: Dysregulation of CD79B signaling has been implicated in the development of autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. Abnormal activation of B cells through the BCR complex, including CD79B, can contribute to the production of autoantibodies and the breakdown of self-tolerance.
•  B-cell lymphomas: Alterations in CD79B expression or mutations in the CD79B gene have been found in different types of B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma. These abnormalities can lead to constitutive BCR signaling and contribute to the growth and survival of lymphoma cells.
•  Autoimmune diseases: CD79B has been implicated in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. Dysregulated BCR signaling mediated by CD79B can result in the production of autoantibodies and immune dysregulation.

•  B-cell lymphomas: Alterations in CD79B expression or mutations in the CD79B gene have been found in different types of B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma. These abnormalities can lead to constitutive BCR signaling and contribute to the growth and survival of lymphoma cells.
•  Autoimmune diseases: CD79B has been implicated in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis. Dysregulated BCR signaling mediated by CD79B can result in the production of autoantibodies and immune dysregulation.